• PDF: Immediate delivery

Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The

  • Publication Date:January 2007
  • Publisher:Arrowhead
  • Product Type: Report
  • Pages:488

Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The

With a market size of US$14.5 billion in 2005 and an anticipated value of US$16.5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry. An increase in the number of aged people, increased life expectancy, unmet clinical needs together with advances in treatments of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease will continue to contribute to the expansion of the global market.

This report provides an insight into the neurodegenerative market, neurotherapeutic drugs currently available, and upcoming products. This report specifically focuses on key CNS diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, and neuropathies. Profiles of leading companies that are active in R&D in these areas are included.

The report presents, in detail, an overview of the current global market for neurodegenerative drugs for selected neurological diseases, including currently marketed and forthcoming neurotherapeutic products. Market analysis and assessment for key neurodegenerative therapies is done across major pharmaceutical markets in United States (US)/North America, Europe and Japan.

Key features of this report:

  • Statistical information for selected neurological diseases
  • Overview of the disease, key therapies, market size and growth, market composition by region, as well as market outlook and forecast
  • Global sales figures for key neurodegenerative therapies
  • Financial forecasts by disease and key product
  • Description of neurotherapeutic products currently on the market, including a description of products in the pipeline
  • Company profiles of major pharmaceutical providers active in R&D in these areas
  • The report also deals with factors affecting growth, new drug therapies, and clinical research in the completion stages.

The diseases/conditions addressed in the report include:

  • Alzheimer's disease
  • Parkinson's disease
  • Multiple sclerosis
  • Amyotrophic lateral sclerosis
  • Huntington's disease
  • Neuropathies
  • 1 Executive Summary
    • 1.1 Report Scope
    • 1.2 Definitions
      • 1.2.1 Alzheimer's Disease
      • 1.2.2 Parkinson's Disease
      • 1.2.3 Multiple Sclerosis
      • 1.2.4 Amyotrophic Lateral Sclerosis
      • 1.2.5 Huntington's Disease
      • 1.2.6 Neuropathies
    • 1.3 Report Methodology
    • 1.4 The Market
    • 1.5 Market Composition
    • 1.6 Competitive Profiles
    • 1.7 Factors to Growth
  • 2 The Market
    • 2.1 Global Pharmaceutical Market
    • 2.2 Global Neurodegenerative Market
    • 2.3 Market Size and Growth
    • 2.4 Market Composition
    • 2.5 US/North American Market
      • 2.5.1 Overview
      • 2.5.2 US Neurodegenerative Market
      • 2.5.3 Canadian Neurodegenerative Market
      • 2.5.4 Regulatory Scenario
    • 2.6 European Market
      • 2.6.1 Overview
      • 2.6.2 Regulatory Scenario
    • 2.7 Japanese Market
      • 2.7.1 Overview
      • 2.7.2 Japanese Neurodegenerative Market
      • 2.7.3 Regulatory Scenario
  • 3 Market Composition: Alzheimer's Disease
    • 3.1 Overview
    • 3.2 Risk Factors
    • 3.3 Symptoms
    • 3.4 Therapies
    • 3.5 Market Size and Growth
    • 3.6 Market Composition
    • 3.7 By Region
    • 3.8 Major Players
    • 3.9 Anti-Alzheimer's Disease Products
      • 3.9.1 AChE inhibitors
      • 3.9.2 NMDA Antagonists
    • 3.10 Incidence of Alzheimer's Disease
    • 3.11 In the Pipeline
    • 3.12 Looking Ahead
    • 3.13 Key Clinical Trials
    • 3.14 Key Emerging Therapies
    • 3.15 Research and Development Trends
  • 4 Market Composition: Parkinson's Disease
    • 4.1 Overview
    • 4.2 Risk Factors
    • 4.3 Symptoms
    • 4.4 Therapies
    • 4.5 Market Size and Growth
    • 4.6 Market Composition by Region
    • 4.7 Major Players
    • 4.8 Anti-Parkinson's Disease Products
      • 4.8.1 Anticholinergics
      • 4.8.2 COMT Inhibitors
      • 4.8.3 Combination Anti-Parkinson's Agents
      • 4.8.4 Dopamine Receptor Agonists
      • 4.8.5 Carbidopa Levodopa Preparations
      • 4.8.6 MAO-B inhibitors
      • 4.8.7 Amantadine
    • 4.9 Incidence and Prevalence of Parkinson's Disease
    • 4.10 In the Pipeline
    • 4.11 Looking Ahead
    • 4.12 Key Clinical Trials
    • 4.13 Key Emerging Therapies
    • 4.14 Key Types of Therapies in Development
  • 5 Market Composition: Multiple Sclerosis
    • 5.1 Overview
    • 5.2 Risk Factors
    • 5.3 Symptoms
    • 5.4 Therapies
    • 5.5 Market Size and Growth
    • 5.6 Market Composition
    • 5.7 Major Players
    • 5.8 Multiple Sclerosis Products
      • 5.8.1 Avonex
      • 5.8.2 Betaseron
      • 5.8.3 Rebif
      • 5.8.4 Copaxone
      • 5.8.5 Novantrone
      • 5.8.6 Symptomatic Relief
    • 5.9 Incidence of Multiple Sclerosis
    • 5.10 In the Pipeline
    • 5.11 Looking Ahead
    • 5.12 Key Emerging Therapies
    • 5.13 Key Late-Stage Clinical Therapeutics
    • 5.14 Key Clinical Trials
  • 6 Market Composition: Amyotrophic Lateral Sclerosis
    • 6.1 Overview
    • 6.2 Risk Factors
    • 6.3 Symptoms
    • 6.4 Therapies
    • 6.5 Major Players
    • 6.6 Anti-Amyotrophic Lateral Sclerosis Products
    • 6.7 Incidence of Anti-Amyotrophic Lateral Sclerosis
    • 6.8 In the Pipeline
    • 6.9 Key Emerging Therapies
    • 6.10 Key Clinical Trials
  • 7 Market Composition: Huntington's Disease
    • 7.1 Overview
    • 7.2 Risk Factors
    • 7.3 Symptoms
    • 7.4 Therapies
    • 7.5 Market Size and Growth
    • 7.6 Market Composition by Region
    • 7.7 Major Players
    • 7.8 Anti-Huntington's Disease Products
      • 7.8.1 Neuroleptics
      • 7.8.2 Benzodiazepines
    • 7.9 Incidence of Huntington's Disease
    • 7.10 In the Pipeline
    • 7.11 Key Emerging Therapies
  • 8 Neuropathies
    • 8.1 Overview
    • 8.2 Risk Factors
    • 8.3 Symptoms
    • 8.4 Therapies
    • 8.5 Market Size and Growth
    • 8.6 Anti-Neuropathies Products
      • 8.6.1 Anticonvulsants
      • 8.6.2 Antidepressants
      • 8.6.3 Analgesics
      • 8.6.4 Others
    • 8.7 Incidence of Neuropathies
    • 8.8 In the Pipeline
    • 8.9 Looking Ahead
    • 8.10 Key Emerging Therapies
    • 8.11 Key Clinical Trials
  • 9 Competitive Profiles
    • 9.1 Amarin
      • 9.1.1 Product Pipeline
      • 9.1.2 Key Financials
    • 9.2 AstraZeneca
      • 9.2.1 Product Portfolio
      • 9.2.2 Product Pipeline
      • 9.2.3 Key Financials
    • 9.3 Avanir
      • 9.3.1 Product Portfolio
      • 9.3.2 Product Pipeline
      • 9.3.3 Key Financials
    • 9.4 Avigen
      • 9.4.1 Product Pipeline
      • 9.4.2 Key Financials
    • 9.5 Biogen Idec
      • 9.5.1 Product Portfolio
      • 9.5.2 Product Pipeline
      • 9.5.3 Key Financials
    • 9.6 Boehringer Ingelheim
      • 9.6.1 Product Portfolio
        • 9.6.1.1 Key Financials
    • 9.7 Daiichi Sankyo
      • 9.7.1 Product Portfolio
      • 9.7.2 Key Financials
    • 9.8 Eisai
      • 9.8.1 Product Portfolio
      • 9.8.2 Product Pipeline
      • 9.8.3 Key Financials
    • 9.9 Elan
      • 9.9.1 Product Portfolio
      • 9.9.2 Product Pipeline
      • 9.9.3 Key Financials
    • 9.10 Eli Lilly
      • 9.10.1 Product Portfolio
      • 9.10.2 Product Pipeline
      • 9.10.3 Key Financials
    • 9.11 Forest Laboratories
      • 9.11.1 Product Portfolio
      • 9.11.2 Product Pipeline
      • 9.11.3 Key Financials
    • 9.12 Genzyme
      • 9.12.1 Product Pipeline
      • 9.12.2 Key Financials
    • 9.13 GlaxoSmithKline
      • 9.13.1 Product Portfolio
      • 9.13.2 Product Pipeline
      • 9.13.3 Key Financials
    • 9.14 Guilford Pharmaceuticals/MGI Pharma
      • 9.14.1 Product Pipeline
      • 9.14.2 Key Financials
    • 9.15 IVAX
      • 9.15.1 Product Portfolio
      • 9.15.2 Key Financials
    • 9.16 Johnson & Johnson
      • 9.16.1 Product Portfolio
      • 9.16.2 Product Pipeline
      • 9.16.3 Key Financials
    • 9.17 Kyowa Hakko Kogyo
      • 9.17.1 Product Portfolio
      • 9.17.2 Product Pipeline
      • 9.17.3 Key Financials
    • 9.18 Lundbeck
      • 9.18.1 Product Portfolio
      • 9.18.2 Product Pipeline
      • 9.18.3 Key Financials
    • 9.19 Merck KGaa
      • 9.19.1 Product Portfolio
      • 9.19.2 Product Pipeline
      • 9.19.3 Key Financials
    • 9.20 Mitsubishi Pharma
      • 9.20.1 Product Portfolio
      • 9.20.2 Product Pipeline
      • 9.20.3 Key Financials
    • 9.21 Novartis
      • 9.21.1 Product Portfolio
      • 9.21.2 Product Pipeline
      • 9.21.3 Key Financials
    • 9.22 Pain Therapeutics
      • 9.22.1 Product Pipeline
      • 9.22.2 Key Financials
    • 9.23 Pfizer
      • 9.23.1 Product Portfolio
      • 9.23.2 Product Pipeline
      • 9.23.3 Key Financials
    • 9.24 Prestwick Pharmaceuticals
      • 9.24.1 Product Pipeline
    • 9.25 Roche
      • 9.25.1 Product Pipeline
      • 9.25.2 Key Financials
    • 9.26 Sanofi-Aventis
      • 9.26.1 Product Portfolio
      • 9.26.2 Product Pipeline
      • 9.26.3 Key Financials
    • 9.27 Schering AG
      • 9.27.1 Product Portfolio
      • 9.27.2 Product Pipeline
      • 9.27.3 Key Financials
    • 9.28 Shire Plc
      • 9.28.1 Product Portfolio
      • 9.28.2 Product Pipeline
      • 9.28.3 Key Financials
    • 9.29 Solvay
      • 9.29.1 Product Portfolio
      • 9.29.2 Product Pipeline
      • 9.29.3 Key Financials
    • 9.30 Takeda
      • 9.30.1 Product Pipeline
      • 9.30.2 Key Financials
    • 9.31 Teva
      • 9.31.1 Product Portfolio
      • 9.31.2 Product Pipeline
      • 9.31.3 Key Financials
    • 9.32 Valeant Pharmaceuticals
      • 9.32.1 Product Portfolio
      • 9.32.2 Product Pipeline
      • 9.32.3 Key Financials
    • 9.33 Wyeth
      • 9.33.1 Product Portfolio
      • 9.33.2 Product Pipeline
      • 9.33.3 Key Financials
  • 10 Factors to Growth
    • 10.1 Demographic
    • 10.2 Healthcare Spends
    • 10.3 Disease Conditions
    • 10.4 Patent Expiry of Popular Products
    • 10.5 New Drug Therapies
    • 10.6 Growth of Generics
      • 10.6.1 Key Facts about Generics
      • 10.6.2 Generics in the Future
  • Appendices
    • Appendix A: Patent Expiries
    • Appendix B: Alzheimer's Disease Clinical Research
    • Appendix C: Parkinson's Disease Clinical Research
    • Appendix D: Multiple Sclerosis Clinical Research
    • Appendix E: Amyotrophic Lateral Sclerosis Clinical Research
    • Appendix F: Huntington's Disease Clinical Research
    • Appendix G: Neuropathies Clinical Research
    • Appendix H: Notes on Related Dementias (RD)
    • Appendix I: Notes on Parkinsonism
  • List of Tables
    • Table 10.2 World Market for Neurodegenerative Drug, 2006-2010 ($ mn)
    • Table 2.1 United States Health Insurance Expenditures by Type of Expenditure
    • Table 2.2 Visits made to physicians by age group and sex (%)
    • Table 2.3 Usage of Prescription Drugs by Type
    • Table 2.4 Cholinesterase Inhibitors Expenditure per 1000 Persons Aged 65
    • Table 3.1 World Market for Alzheimer's Disease by Region, 2005 ($)
    • Table 3.2 Global Sales (2001 - 2005) - Aricept ($ mn)
    • Table 3.3 Global Sales Forecast (2006-2010) - Aricept ($ mn)
    • Table 3.4 Global Sales (2001 - 2005) - Exelon ($ mn)
    • Table 3.5 Global Sales Forecast (2006-2010) - Exelon ($ mn)
    • Table 3.6 Global Sales (2001 - 2005) - Reminyl ($ mn)
    • Table 3.7 Global Sales Forecast (2006-2010) - Reminyl ($ mn)
    • Table 3.8 Global Sales Forecast (2004-2010) - Namenda/Ebixia ($ mn)
    • Table 3.9 Alzheimer's Disease Incidence
    • Table 3.10 Prevalence of Alzheimer's Disease - (Million)
    • Table 3.11 Alzheimer's Disease Pipeline
    • Table 3.12 World Market for Anti-Alzheimer's Products, 2006-2010 ($ mn)
    • Table 4.1 World Market for Parkinson's Disease by Region, 2005 ($)
    • Table 4.2 Global Sales Forecast - Comtan ($ mn)
    • Table 4.3 Global Sales Forecast - Tasmar ($mn)
    • Table 4.4 Global Sales Forecast - Stalevo ($ mn)
    • Table 4.5 Global Sales Forecast - Mirapex/Sifrol ($mn)
    • Table 4.6 Global Sales - Requip ($ mn)
    • Table 4.7 Global Sales Forecast - Requip ($ mn)
    • Table 4.8 Prevalence of Parkinson's Disease (mn)
    • Table 4.9 Parkinson's Disease Pipeline
    • Table 4.10 World Market for Anti-Parkinson's Products, 2006-2010 ($ mn)
    • Table 4.11 Available and Emerging Drugs for Parkinson's Disease
    • Table 5.1 Global Sales - Avonex ($ mn)
    • Table 5.2 Global Sales Forecast - Avonex ($ mn)
    • Table 5.3 Global Sales - Betaseron ($ mn)
    • Table 5.4 Global Sales Forecast - Betaseron ($ mn)
    • Table 5.5 Global Sales - Rebif ($ mn)
    • Table 5.6 Global Sales forecast - Rebif ($ mn)
    • Table 5.7 Global Sales - Copaxone ($ mn)
    • Table 5.8 Global Sales Forecast - Copaxone ($ mn)
    • Table 5.9 Multiple Sclerosis Pipeline
    • Table 5.10 Forecast of Multiple Sclerosis Drug Market, 2006-2010 ($ mn)
    • Table 6.1 Amyotrophic Lateral Sclerosis Pipeline
    • Table 7.1 Global Sales Forecast - Risperdal ($ mn)
    • Table 7.2 Huntington's Disease Pipeline
    • Table 8.1 Global Sales - Tegretol ($ mn)
    • Table 8.2 Global Sales Forecast - Tegretol ($ mn)
    • Table 8.3 Global Sales - Neurontin ($ mn)
    • Table 8.4 Global Sales Forecast - Neurontin ($ mn)
    • Table 8.5 Global Sales Forecast - Cymbalta ($ mn)
    • Table 8.6 Global Sales Forecast - Lyrica ($ mn)
    • Table 8.7 Neuropathies Pipeline
    • Table 8.8 Global Neuropathic Pain Market ($ mn)
    • Table 9.1 Companies Active in Neurodegenerative Research, by Condition
    • Table 10.1 Major US Patent Expiries 2005-2007
  • List of Graphs
    • Graphs
    • Graph 2.1 Global Pharmaceutical Sales 2001-2005
    • Graph 2.2 Global Pharmaceutical Sales by Region, 2005**
    • Graph 2.3 Leading Products by Global Pharmaceutical Sales, 2005**
    • Graph 2.4 Leading Therapy Classes by Global Pharmaceutical Sales, 2005**
    • Graph 2.5 Number of Parkinson Drug Prescriptions Dispensed
    • Graph 2.6 Recommended Drug Therapies for Parkinson's Disease
    • Graph 3.1 World Market for Alzheimer's Disease by Region, 2005 (%)
    • Graph 3.2 Alzheimer's Disease Prevalence
    • Graph 4.1 World Market for Parkinson's Disease by Region, 2005 (%)
    • Graph 5.1 Market Share of Leading Multiple Sclerosis Therapies, 2005
    • Graph 8.1 Top Causes of Pain
    • Graph 10.1 Percentage Increase in Age 60 and Over by Region, 2000-2050
    • Graph 10.2 World Aging Trends
    • Graph 10.3 Health Spending in Organization for Economic Co-operation and Development (OECD) Countries as % of GDP, 2003
    • Graph 10.4 Government Expenditure on Health
    • Graph 10.5 U.S. Growth of Generics, 1984-2005
    • Graph 10.6 U.S. Generics vs. Brand-Name Pharmaceuticals Sales, 2005
    • Graph 10.7 Generic Drug Sales in U.S. (projected)
+44 20 8816 8548

Ask a question about Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The

Enter the characters you see in the picture below
Captcha